Synairgen plc Presentation at ECCMID
25 Abril 2022 - 1:01AM
RNS Non-Regulatory
TIDMSNG
Synairgen plc
25 April 2022
Synairgen plc
('Synairgen' or the 'Company')
Synairgen Presented Phase 2 Sub-group Analysis for SNG001 in
COVID-19 at the European Congress of Clinical Microbiology &
Infectious Diseases
Southampton, UK - 25 April 2022: Synairgen plc (LSE: SNG), the
respiratory company developing SNG001, an investigational
formulation for inhalation containing the broad-spectrum antiviral
protein interferon beta, presented the sub-group analysis from its
Phase 2, SG016 study on Saturday 23 April in an oral presentation
at the 32nd European Congress of Clinical Microbiology &
Infectious Diseases (ECCMID), held in Lisbon, Portugal from 23-26
April 2022.
The positive results of this Phase 2 study (SG016) in the
hospital setting were first announced in July 2020 and published in
The Lancet Respiratory Medicine in November 2020.
ECCMID 2022:
Oral Presentation:
Title : Effects of Inhaled interferon beta on hospitalised
COVID-19 patients receiving supplemental oxygen
Abstract Number : 02567
Session type : 1-Hour Mini-oral Flash Session
Session name : COVID-19 treatment insights and advances
Session date and time : 23 April 2022 at 11:00 WEST
The poster presentation is now available on the Synairgen
website. For further information on ECCMID visit:
https://www.eccmid.org/
ATS 2022:
Further analysis of the SPRINTER trial data will be presented at
the ATS 2022 International Conference, being held between 13-18 May
2022 in San Francisco.
For further enquiries, please contact:
Synairgen plc
Brooke Clarke, Head of Communications
Media@synairgen.com
Tel: + 44 (0) 23 8051 2800
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Namrata Taak
cscsynairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516-606-6545
Notes for Editors
About the Phase 2 study (SG016, NCT04385095)
SG016 was a double-blind, placebo-controlled trial. The
220-patient trial comprised c. 100 patients initiated in hospital
and 120 patients initiated in the home setting. The patients that
participated in the hospital setting, which completed recruitment
in May 2020, were recruited across a number of NHS trusts and the
trial had been adopted by the NIHR Respiratory Translational
Research Collaboration which is comprised of leading centres in
respiratory medicine in the UK whose internationally recognised
experts are working together to accelerate development and
discovery for COVID-19.
About SNG001
SNG001 is a pH-neutral formulation of interferon-beta (IFN-beta)
for inhalation that is delivered directly into the lungs using a
mesh nebuliser, currently being investigated as a potential
host-directed antiviral treatment for COVID-19 patients.
The SARS-CoV-2 virus has been shown to suppress the production
of IFN-beta, a naturally occurring protein that orchestrates the
body's antiviral defences, with the aim of evading host immune
responses. By administering IFN-beta into the lungs, the aim is to
correct this deficiency, potentially switching back on the lungs'
antiviral pathways to clear the virus. SNG001 has been shown to
demonstrate potent in vitro antiviral activity against a broad
range of viruses including COVID-19 and Alpha, Beta, Gamma, Delta
and Omicron variants.
About Synairgen
Synairgen is a UK-based respiratory company focused on drug
discovery, development and commercialisation. The Company's primary
focus is developing SNG001 (inhaled interferon beta) for the
treatment of COVID-19 as potentially the first host-targeted,
broad-spectrum antiviral treatment delivered directly into the
lungs. SNG001 has been granted Fast Track status from the US Food
and Drug Administration (FDA) and the Phase 3 SPRINTER trial was
deemed an Urgent Public Health study by the UK's National Institute
for Health Research (NIHR). The topline data from Synairgen's Phase
3 clinical programme evaluating SNG001 in patients across 17
countries was announced in February 2022 and detailed analysis of
the data is ongoing.
Founded by University of Southampton Professors Sir Stephen
Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is
quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABZLLLLZLBBBQ
(END) Dow Jones Newswires
April 25, 2022 02:01 ET (06:01 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024